Insider Purchase at Micron & Potential Deals at Eli Lilly – The Special Situations Report Episode #50

Episode Summary

Executive Summary: Episode 50 of Special Situations Report surveys a busy week in event-driven markets: rumored and announced M&A in shale energy, biotech, medtech, airlines, and avocado growers; a new defense spin-off; a first-ever buyback at Veeva Systems; a rare major insider buy at Micron by ex-TSMC CEO Tien Wu Liu; and sweeping management changes at Under Armour amid a deep turnaround effort.

Main Topics: Energy deal rumors: Devon Energy and Coterra (Priority: 5/5): Reuters reported Devon Energy and Coterra are exploring a merger that could create one of the largest independent U.S. shale producers. The hosts compare it to prior all-stock oil deals like Pioneer/Exxon and discuss production mix, valuation, free cash flow, dividends, and likely low antitrust risk. Eli Lilly’s acquisition push in biotech (Priority: 5/5): The discussion covers Lilly’s completed acquisition of Verve Therapeutics and its rumored/possible cross-border bid for Abivax. The hosts highlight Lilly’s strategic expansion beyond diabetes/obesity into inflammatory and obesity-linked cardiovascular therapies, while noting regulatory and foreign-investment approval risks in France. Announced M&A: Boston Scientific acquiring Penumbra (Priority: 5/5): Boston Scientific’s $14.5 billion cash-or-stock acquisition of Penumbra is framed as its largest deal in two decades and a major expansion in thrombectomy and stroke treatment. The hosts analyze the spread, regulatory scrutiny, and why a long outside date suggests antitrust caution. Shareholder-friendly capital return at Veeva Systems (Priority: 4/5): Veeva announced a $2 billion buyback, notable because the company has historically avoided dividends and repurchases. The hosts review Veeva’s life-sciences software moat, CRM transition away from Salesforce, customer concentration risk, and valuation/margin pressure concerns. Insider signal: Micron director Tien Wu Liu’s large purchase (Priority: 5/5): A rare and very large insider buy at Micron by director Tien Wu Liu is interpreted as a strong confidence signal from a former TSMC co-CEO. The hosts tie the purchase to AI-driven memory demand, especially HBM for GPUs, while warning that a future AI capex slowdown could reverse the cycle. Under Armour turnaround and executive churn (Priority: 4/5): Prem Watsa’s large purchase of Under Armour is discussed alongside ongoing executive turnover, weak operating results, and the end of the Steph Curry relationship. The hosts debate whether this is a real value opportunity or another legacy-brand turnaround trap. Smaller event-driven items: spin-off and deal updates (Priority: 3/5): L3Harris announced a missile-solutions spin-off backed by a $1 billion Department of Defense minority investment, while the failed Alcon-Star Surgical deal and the announced Sun Country/Allegiant and Calavo/Mission Produce transactions round out the week’s special situations flow.

Key Arguments: Large oil-and-gas combinations such as Devon/Coterra can be attractive despite weak commodity cycles because they still generate substantial free cash flow and likely face limited antitrust issues in a fragmented upstream market. For merger arbitrage, pre-deal rumor price matters more than headline premium from the last close; Lilly’s Verve deal illustrated how a small premium on the announcement day can still represent a huge gain versus the rumor price. Eli Lilly appears to be using M&A to broaden beyond diabetes and obesity into inflammatory and obesity-related cardiovascular and immunology-adjacent therapies, suggesting a deliberate pipeline-expansion strategy. Cross-border approvals can materially widen spreads and delay execution; Abivax’s proposed sale to Lilly depends on French foreign-investment review, creating geopolitical and regulatory uncertainty. Boston Scientific’s Penumbra deal is strategically logical because it expands a cardiovascular med-tech platform into clot removal and stroke care, but the size and overlap justify a long regulatory timetable. Veeva remains a high-quality, sticky SaaS business with deep life-sciences penetration, but its valuation is still rich and the CRM migration plus AI-related margin pressure could limit near-term upside. Micron’s huge insider buy from a highly credible semiconductor veteran is meaningful because it came after strong AI-memory demand and a supply-driven earnings surge, but it also raises the risk/reward question of whether the cycle becomes secular or reverts sharply. Under Armour’s large insider and sponsor-related buying does not erase the reality of declining revenue, losses, executive turnover, and brand erosion; turnarounds in legacy consumer brands often fail despite apparently cheap stocks.

Data Points: Completed deals in 2025: 206 - Referenced as part of a strong year for M&A activity. Deals in the works tracked in 2025: 190 - Potential transactions being monitored by the hosts. Pioneer rumor price: about $215/share - Wall Street Journal report before Exxon’s eventual acquisition. Pioneer deal value: about $255/share - Confirmed acquisition price for Pioneer Natural Resources. Devon market cap: nearly $23 billion - Scale comparison for a potential Devon-Coterra merger. Devon enterprise value: $30 billion - Scale comparison for a potential Devon-Coterra merger. Coterra market cap: approaching $20 billion - Scale comparison for a potential Devon-Coterra merger. Coterra enterprise value: a little under $24 billion - Scale comparison for a potential Devon-Coterra merger. Coterra free cash flow: more than $1.4 billion - Last four quarters. Devon free cash flow: over $3 billion - Last four quarters. Coterra dividend yield: 3.42% - Compared with Devon’s yield. Devon dividend yield: 2.65% - Compared with Coterra’s yield. Devon payout ratio: 22% - Described as one of the lowest in the oil patch. Lilly-Verve deal value: more than $1 billion - Initial reported size of the Verve Therapeutics acquisition. Verve acquisition price: $14/share - Officially announced acquisition price. Verve premium to last close: 2% - Announcement-day premium. Verve premium to rumor price: over 100% - Because the stock had traded around $7 before rumors. Abivax rumored bid: 15 billion euros / $17.45 billion - Potential cross-border acquisition by Eli Lilly. Boston Scientific-Penumbra deal value: $14.5 billion - Announced acquisition value. Penumbra consideration: $374/share - Cash or stock election value for shareholders. Penumbra stock alternative: 3.87 shares of Boston Scientific common stock - Stock consideration election. Penumbra spread: 6.62% - Merger-arbitrage spread at the time discussed. Sun Country-Allegiant deal value: $1.5 billion - Discount-airline merger announcement. Sun Country-Allegiant spread: 2.17% - Indicating low perceived regulatory risk. Calavo-Mission Produce deal value: $430 million - Announced avocado grower transaction. Calavo purchase price: $27/share - Cashless stock deal value per share. Prior Calavo rumor price: $32/share - Earlier rumored bid level from June 2025. L3Harris spin-off investment: $1 billion - Minority investment from the U.S. Department of Defense. Veeva buyback size: $2 billion - Share repurchase authorization. Veeva buyback as % of market cap: about 5.5% - At the time of announcement. Veeva customers: over 1,400 - Global customer base. Veeva penetration of top pharma: 19 of the world’s 20 largest pharmaceutical companies - Demonstrates the company’s moat and reach. Veeva CRM contribution: about 20% of revenue - Down from roughly 25% two years earlier. Veeva live Vault CRM customers: over 115 - Adoption progress after migration from Salesforce. Veeva expected top-20 pharma adoption: about 14 of the top 20 - Management’s current expectation for Vault CRM uptake. Veeva top 10 customer concentration: about 28% of revenue - Fiscal 2025 concentration risk. Micron quarterly revenue: nearly $14 billion - Fiscal Q1 2026 results. Micron DRAM mix: 79% of revenue - Share of revenue from DRAM sales. Micron NAND mix: 20% of revenue - Share of revenue from NAND sales. Micron DRAM growth: 69% year over year - Fiscal Q1 2026. Micron NAND growth: 22% year over year - Fiscal Q1 2026. Micron share price at discussion: $362.75 - Recent trading level after a strong rally. Micron prior low: below $65/share - During tariff-related fears in April. Micron insider purchase size: 23,200 shares - Bought by director Tien Wu Liu. Micron insider purchase value: nearly $8 million - Average price $337.14 per share. Micron first insider purchase in over: 8 years - First insider purchase of any kind at Micron in over eight years. Micron board member background: 30 years at TSMC; co-CEO 2013-2018; executive chairman 2018-2024 - Used to support the credibility of the buy. Under Armour revenue change: down 5% year over year - Fiscal Q2 2026. Under Armour net result: $19 million net loss - Compared with prior-year profit. Under Armour prior-year net income: $170 million - Same quarter one year earlier. Under Armour stock performance: down 33% in the last year - Reflecting operational deterioration. Under Armour five-year stock decline: over two-thirds - Longer-term underperformance.

Pivotal Quotes: "One of these rumored deals that I participated in personally was the shale oil production company, Pioneer Natural Resources, which was acquired by ExxonMobil." — Asip Surya: Illustrating how rumor-driven deal trading can later convert into a successful merger-arbitrage opportunity. "This is probably one of my favorite insider situations, and we came across it last Thursday night when you and I were reviewing insider purchases from that day for inclusion in the Friday event-event monitor." — Asip Surya: Introducing Micron director Tien Wu Liu’s unusually large purchase as a strong insider signal. "Prem Watsa has historically been caught in value traps like BlackBerry, where legacy impressions outweigh the current financial outlook." — Tamana Surya: Framing the skeptical view of Under Armour as a turnaround candidate despite large insider buying.

Implications: Listeners should expect more event-driven opportunities in energy, biotech, medtech, and semiconductors, but also more regulatory and cycle risk. Strong insider buying and buybacks can matter, yet valuation, execution, and macro/AI-cycle shifts will likely determine outcomes.